Li Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li Yang has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Jing Peng
Department of Pediatrics Xiangya Hospital of Central South University Changsha China
6 shared publications Tenghui Wu
Department of Pediatrics Xiangya Hospital of Central South University Changsha China
4 shared publicationsChen Chen
Department of Pediatrics Xiangya Hospital of Central South University Changsha China
3 shared publicationsCunhui Pan
Department of Pediatrics, Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
3 shared publicationsFei Yin
Department of Pediatrics Xiangya Hospital of Central South University Changsha China
3 shared publications- Fei Yin
Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China
3 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8)
Genotypic and Phenotypic Profile of 50 Cases With Chromatin Remodeling Complexes‐Related Neurological Disorders
Aim: To describe the genotypic and phenotypic profile of chromatin remodeling complex (CRC)‐related neurological disorders. Methods: We retrospectively analyzed the clinical characteristics and the genetic spectrum of children with variants in CRC genes. Results: Fifty patients were included. The genotype spectrum involved genes encoding the CHD complex ( CHD2 , CHD3 , CHD4 , CHD7 , CHD8 ), the BAF complex ( SMARCA2 , ARID1B , ARID2 , ACTB ), and the ISWI complex ( BPTF ). The predominant phenotypes were global developmental delay/intellectual disability (GDD/ID) (76.0%, 38/50) and epilepsy (64.0%, 32/50). Seventy‐five percent of patients with epilepsy had generalized seizures. Sixty‐nine percent (20/29) were seizure‐free for more than 1 year at the last follow‐up (three were lost to follow‐up), although 56.3% (18/32) of patients required three or more kinds of antiseizure medications. EEG abnormalities were prevalent (82.2%, 37/45), commonly showing generalized or diffuse interictal discharges (63.6%), slow background activity (59.5%), and slow waves (35.1%). BAF complex variants were significantly associated with GDD/ID, microcephaly, facial dysmorphism, short stature, and slow background activity on EEG, while CHD complex variants were more likely to cause heat‐sensitive seizures (FDR < 0.05). Conclusion: CRC‐related disorders are primarily caused by variants in the CHD and BAF complexes, with CHD2 , ARID1B , and SMARCA2 being the frequently involved genes. The conditions are characterized by GDD/ID and epilepsy, with distinct clinical patterns between the CHD and BAF complexes.
- 29 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8)
Open AccessGenotypic and Phenotypic Profile of 50 Cases With Chromatin Remodeling Complexes‐Related Neurological Disorders
Aim: To describe the genotypic and phenotypic profile of chromatin remodeling complex (CRC)‐related neurological disorders. Methods: We retrospectively analyzed the clinical characteristics and the genetic spectrum of children with variants in CRC genes. Results: Fifty patients were included. The genotype spectrum involved genes encoding the CHD complex ( CHD2 , CHD3 , CHD4 , CHD7 , CHD8 ), the BAF complex ( SMARCA2 , ARID1B , ARID2 , ACTB ), and the ISWI complex ( BPTF ). The predominant phenotypes were global developmental delay/intellectual disability (GDD/ID) (76.0%, 38/50) and epilepsy (64.0%, 32/50). Seventy‐five percent of patients with epilepsy had generalized seizures. Sixty‐nine percent (20/29) were seizure‐free for more than 1 year at the last follow‐up (three were lost to follow‐up), although 56.3% (18/32) of patients required three or more kinds of antiseizure medications. EEG abnormalities were prevalent (82.2%, 37/45), commonly showing generalized or diffuse interictal discharges (63.6%), slow background activity (59.5%), and slow waves (35.1%). BAF complex variants were significantly associated with GDD/ID, microcephaly, facial dysmorphism, short stature, and slow background activity on EEG, while CHD complex variants were more likely to cause heat‐sensitive seizures (FDR < 0.05). Conclusion: CRC‐related disorders are primarily caused by variants in the CHD and BAF complexes, with CHD2 , ARID1B , and SMARCA2 being the frequently involved genes. The conditions are characterized by GDD/ID and epilepsy, with distinct clinical patterns between the CHD and BAF complexes.
- Open Access
- 7 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (7) , e71013
Loss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy
Aim: To delineate the clinical features of AFG3L2 ‐related developmental and epileptic encephalopathy (DEE) and explore its pathogenic mechanisms. Methods: Whole‐genome and blood transcriptome sequencing were performed in undiagnosed DEE patients. Patient‐derived skin fibroblasts were established for the analysis of RNA and protein expression as well as for mitochondrial functional assays, including OPA1 processing, mtDNA copy number, membrane potential, ATP production, mitochondrial morphology analysis, and mitochondrial stress testing. Additionally, published AFG3L2 ‐related epilepsy cases were systematically reviewed. Results: We identified four novel AFG3L2 variants in four DEE patients from two unrelated families, including splice‐site/intronic variants in one family and exon‐deletion/intronic variants in the other, fitting a recessive model of disease. In these patients, plus six additional previously reported DEE patients, symptoms included severe developmental delay, intractable seizures, microcephaly, generalized spasticity, and progressive cerebral atrophy. Transcriptome and fibroblast functional analyses revealed aberrant splicing, reduced AFG3L2 expression, defective OPA1 processing, decreased mtDNA content, impaired membrane potential and ATP production, fragmented mitochondrial networks, and diminished respiratory capacity, supporting a loss‐of‐function mechanism. Compared with spastic ataxia 5—usually involving null‐missense or missense‐missense genotypes—DEE predominantly features null‐null combinations. Significance: We implicate AFG3L2 as a novel causative gene for DEE, likely through mitochondrial proteostasis failure and bioenergetic compromise, expanding the phenotypic and genotypic spectrum of AFG3L2 ‐related disorders.
- 7 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (7) , e71013
Open AccessLoss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy
Aim: To delineate the clinical features of AFG3L2 ‐related developmental and epileptic encephalopathy (DEE) and explore its pathogenic mechanisms. Methods: Whole‐genome and blood transcriptome sequencing were performed in undiagnosed DEE patients. Patient‐derived skin fibroblasts were established for the analysis of RNA and protein expression as well as for mitochondrial functional assays, including OPA1 processing, mtDNA copy number, membrane potential, ATP production, mitochondrial morphology analysis, and mitochondrial stress testing. Additionally, published AFG3L2 ‐related epilepsy cases were systematically reviewed. Results: We identified four novel AFG3L2 variants in four DEE patients from two unrelated families, including splice‐site/intronic variants in one family and exon‐deletion/intronic variants in the other, fitting a recessive model of disease. In these patients, plus six additional previously reported DEE patients, symptoms included severe developmental delay, intractable seizures, microcephaly, generalized spasticity, and progressive cerebral atrophy. Transcriptome and fibroblast functional analyses revealed aberrant splicing, reduced AFG3L2 expression, defective OPA1 processing, decreased mtDNA content, impaired membrane potential and ATP production, fragmented mitochondrial networks, and diminished respiratory capacity, supporting a loss‐of‐function mechanism. Compared with spastic ataxia 5—usually involving null‐missense or missense‐missense genotypes—DEE predominantly features null‐null combinations. Significance: We implicate AFG3L2 as a novel causative gene for DEE, likely through mitochondrial proteostasis failure and bioenergetic compromise, expanding the phenotypic and genotypic spectrum of AFG3L2 ‐related disorders.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 485
A Heteroplasmic MT-CO2 m.8024G > A Variant Is Associated with Mitochondrial Bioenergetic Deficiency and Optic Atrophy
Leber’s hereditary optic neuropathy (LHON) is a hereditary neurodegenerative disorder caused by pathogenic mitochondrial DNA (mtDNA) variants. While MT-CO2 defects are implicated in neurodegeneration, their direct association with optic atrophy has not been reported. We identify a heteroplasmic MT-CO2 variant, m.8024G > A (p.Glu147Lys), in a patient with progressive optic atrophy and explore its potential association with mitochondrial dysfunction. A 13-year-old male with progressive unilateral-then-bilateral vision loss underwent comprehensive ophthalmic/neurological evaluation, trio whole-exome sequencing, and mtDNA sequencing. The pathogenicity of the identified variant was assessed in patient-derived fibroblasts using mitochondrial stress tests, ATP/ROS assays, enzymatic profiling, BN-PAGE, mitochondrial membrane potential, mtDNA copy number, ultrastructural microscopy, and immunoblotting. Functional analyses revealed that this variant, which reduces the expression of mtDNA-encoded electron transport chain (ETC) subunits and induces severe Complex IV deficiency, reduced cellular oxygen consumption rate (OCR), impaired ATP synthesis, decreased mtDNA copy number, and elevated reactive oxygen species (ROS) production. Concurrently, mutant cells exhibited enhanced mitophagy with preserved flux, a compensatory response to persistent mitochondrial damage. Unlike canonical optic neuropathy associated with homoplasmic mtDNA mutations, this heteroplasmic variant is linked to mitochondrial dysfunction potentially related to tissue-specific heteroplasmy and altered mitophagic responses. We report a heteroplasmic m.8024G > A mutation in MT-CO2 associated with childhood-onset isolated optic atrophy. Functional analyses in patient fibroblasts show that this variant is associated with MT-CO2 structural perturbation, Complex IV dysfunction, altered mitophagy, and mitochondrial energy failure—supporting its potential pathogenic relevance. This study expands the genotypic and phenotypic spectrum of mitochondrial optic neuropathies and provides mechanistic insights into the pathogenesis of heteroplasmic mtDNA variant-related disease.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 485
A Heteroplasmic MT-CO2 m.8024G > A Variant Is Associated with Mitochondrial Bioenergetic Deficiency and Optic Atrophy
Leber’s hereditary optic neuropathy (LHON) is a hereditary neurodegenerative disorder caused by pathogenic mitochondrial DNA (mtDNA) variants. While MT-CO2 defects are implicated in neurodegeneration, their direct association with optic atrophy has not been reported. We identify a heteroplasmic MT-CO2 variant, m.8024G > A (p.Glu147Lys), in a patient with progressive optic atrophy and explore its potential association with mitochondrial dysfunction. A 13-year-old male with progressive unilateral-then-bilateral vision loss underwent comprehensive ophthalmic/neurological evaluation, trio whole-exome sequencing, and mtDNA sequencing. The pathogenicity of the identified variant was assessed in patient-derived fibroblasts using mitochondrial stress tests, ATP/ROS assays, enzymatic profiling, BN-PAGE, mitochondrial membrane potential, mtDNA copy number, ultrastructural microscopy, and immunoblotting. Functional analyses revealed that this variant, which reduces the expression of mtDNA-encoded electron transport chain (ETC) subunits and induces severe Complex IV deficiency, reduced cellular oxygen consumption rate (OCR), impaired ATP synthesis, decreased mtDNA copy number, and elevated reactive oxygen species (ROS) production. Concurrently, mutant cells exhibited enhanced mitophagy with preserved flux, a compensatory response to persistent mitochondrial damage. Unlike canonical optic neuropathy associated with homoplasmic mtDNA mutations, this heteroplasmic variant is linked to mitochondrial dysfunction potentially related to tissue-specific heteroplasmy and altered mitophagic responses. We report a heteroplasmic m.8024G > A mutation in MT-CO2 associated with childhood-onset isolated optic atrophy. Functional analyses in patient fibroblasts show that this variant is associated with MT-CO2 structural perturbation, Complex IV dysfunction, altered mitophagy, and mitochondrial energy failure—supporting its potential pathogenic relevance. This study expands the genotypic and phenotypic spectrum of mitochondrial optic neuropathies and provides mechanistic insights into the pathogenesis of heteroplasmic mtDNA variant-related disease.
- 17 December 2025
- Published by Elsevier in Mitochondrion
- Vol. 87, 102110
Biallelic FOXRED1 mutations cause infantile mitochondrial encephalopathy with complex I disassembly and basal ganglia degeneration
- 17 December 2025
- Published by Elsevier in Mitochondrion
- Vol. 87, 102110
Biallelic FOXRED1 mutations cause infantile mitochondrial encephalopathy with complex I disassembly and basal ganglia degeneration
- Open Access
- 11 July 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-12
The Role of Estrogen in Mitochondrial Disease
This review aims to investigate the potential role of estrogen in various mitochondrial diseases, such as Leber’s Hereditary Optic Neuropathy and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes, focusing on its effects on aging, oxidative stress, mitochondrial biogenesis, and mitophagy. Mitochondrial diseases have become important in modern medical research due to their complex genetic background and diverse clinical manifestations. Studies in recent years have shown that estrogen plays an essential role in physiological regulation and may also affect the health status of cells by regulating mitochondrial function, which in turn affects the occurrence and development of diseases. However, there is still a lack of systematic review of estrogen’s specific mechanisms and roles in these diseases. This review will synthesize the relevant literature to explore the association between estrogen and mitochondrial diseases and its possible therapeutic prospects, aiming to provide a theoretical basis and reference for future research. Graphical Abstract An overview of how estrogen affects mitochondria. Estrogen maintains mitochondrial function and alleviates the aging process. Besides, it has potential therapeutic effects in LHON and MELAS by regulating cellular functions.
- 11 July 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-12
Open AccessThe Role of Estrogen in Mitochondrial Disease
This review aims to investigate the potential role of estrogen in various mitochondrial diseases, such as Leber’s Hereditary Optic Neuropathy and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes, focusing on its effects on aging, oxidative stress, mitochondrial biogenesis, and mitophagy. Mitochondrial diseases have become important in modern medical research due to their complex genetic background and diverse clinical manifestations. Studies in recent years have shown that estrogen plays an essential role in physiological regulation and may also affect the health status of cells by regulating mitochondrial function, which in turn affects the occurrence and development of diseases. However, there is still a lack of systematic review of estrogen’s specific mechanisms and roles in these diseases. This review will synthesize the relevant literature to explore the association between estrogen and mitochondrial diseases and its possible therapeutic prospects, aiming to provide a theoretical basis and reference for future research. Graphical Abstract An overview of how estrogen affects mitochondria. Estrogen maintains mitochondrial function and alleviates the aging process. Besides, it has potential therapeutic effects in LHON and MELAS by regulating cellular functions.
- 5 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (4) , 167043
MT-TN mutations lead to progressive mitochondrial encephalopathy and promotes mitophagy
- 5 February 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (4) , 167043
MT-TN mutations lead to progressive mitochondrial encephalopathy and promotes mitophagy
- Open Access
Detachment of Dodecane from Silica Surfaces with Variable Surface Chemistry Studied Using Molecular Dynamics Simulation
The adsorption and detachment processes of n-dodecane (C12H26) molecules were studied on silica surfaces with variable surface chemistry (Q2, Q3, Q4 environments), using molecular dynamics simulations. The area density of the silanol groups varied from 9.4 to 0 per nm2. The shrinking of the oil–water–solid contact line was a key step for the oil detachment, due to water diffusion on the three-phase contact line. The simulation results showed that oil detachment was easier and faster on a perfect Q3 silica surface which had (≡Si(OH))-type silanol groups, due to the H-bond formation between the water and silanol groups. When the surfaces contained more Q2 crystalline type which had (≡Si(OH)2)-type silanol groups, less oil detached, due to the formations of H-bonds among the silanol groups. There were no silanol groups on the Si-OH 0 surface. Water cannot diffuse on the water–oil–silica contact line, and oil cannot detach from the Q4 surface. The detachment efficiency of oil from the silica surface not only depended on the area density, but also on the types of silanol groups. The density and type of silanol groups depend on the crystal cleavage plane, particle size, roughness, and humidity.
Open AccessDetachment of Dodecane from Silica Surfaces with Variable Surface Chemistry Studied Using Molecular Dynamics Simulation
The adsorption and detachment processes of n-dodecane (C12H26) molecules were studied on silica surfaces with variable surface chemistry (Q2, Q3, Q4 environments), using molecular dynamics simulations. The area density of the silanol groups varied from 9.4 to 0 per nm2. The shrinking of the oil–water–solid contact line was a key step for the oil detachment, due to water diffusion on the three-phase contact line. The simulation results showed that oil detachment was easier and faster on a perfect Q3 silica surface which had (≡Si(OH))-type silanol groups, due to the H-bond formation between the water and silanol groups. When the surfaces contained more Q2 crystalline type which had (≡Si(OH)2)-type silanol groups, less oil detached, due to the formations of H-bonds among the silanol groups. There were no silanol groups on the Si-OH 0 surface. Water cannot diffuse on the water–oil–silica contact line, and oil cannot detach from the Q4 surface. The detachment efficiency of oil from the silica surface not only depended on the area density, but also on the types of silanol groups. The density and type of silanol groups depend on the crystal cleavage plane, particle size, roughness, and humidity.
- Open Access
- 10 March 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 11 (7) , e2162
Large heterozygous deletion and uniparental disomy masquerading as homozygosity inCHKBgene
Background: CHKBmutations have been described in 49 patients with megaconial congenital muscular dystrophy, which is a rare autosomal recessive disorder, of which 40 patients showed homozygosity.Methods: Peripheral blood genomic DNA samples were extracted from patients and their parents and were tested by whole exome sequencing. Quantitative PCR was performed to detect deletion. Single nucleotide polymorphism analysis was performed to identify uniparental disomy. Quantitative PCR and western blot were used to measure the expression level ofCHKBin patient 1‐derived immortalized lymphocytes. Mitochondria were observed in lymphocytes by electron microscopy.Results: Two unrelated cases born to non‐consanguineous parents were diagnosed with megaconial congenital muscular dystrophy due to apparently homozygous mutations (patient 1: c.225‐2A>T; patient 2: c.701C>T) in theCHKBgene using whole exome sequencing. Quantitative PCR revealed that patient 1 had a large deletion encompassing theCHKBgene, inherited from the mother. Single nucleotide polymorphism analysis revealed patient 2 had paternal uniparental isodisomy containing theCHKBgene. In the immortalized lymphocytes from patient 1, decreased expression ofCHKBwas revealed by quantitative PCR and western blot, and giant mitochondria were observed using electron microscopy.Conclusion: We provide a possibility to detect giant mitochondria in other cells when muscle was not available. Moreover, clinicians should be aware that homozygous variants can be masqueraded by uniparental disomy or large deletions in offspring of non‐consanguineous parents, and excessive homozygosity may be misdiagnosed.
- 10 March 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 11 (7) , e2162
Open AccessLarge heterozygous deletion and uniparental disomy masquerading as homozygosity inCHKBgene
Background: CHKBmutations have been described in 49 patients with megaconial congenital muscular dystrophy, which is a rare autosomal recessive disorder, of which 40 patients showed homozygosity.Methods: Peripheral blood genomic DNA samples were extracted from patients and their parents and were tested by whole exome sequencing. Quantitative PCR was performed to detect deletion. Single nucleotide polymorphism analysis was performed to identify uniparental disomy. Quantitative PCR and western blot were used to measure the expression level ofCHKBin patient 1‐derived immortalized lymphocytes. Mitochondria were observed in lymphocytes by electron microscopy.Results: Two unrelated cases born to non‐consanguineous parents were diagnosed with megaconial congenital muscular dystrophy due to apparently homozygous mutations (patient 1: c.225‐2A>T; patient 2: c.701C>T) in theCHKBgene using whole exome sequencing. Quantitative PCR revealed that patient 1 had a large deletion encompassing theCHKBgene, inherited from the mother. Single nucleotide polymorphism analysis revealed patient 2 had paternal uniparental isodisomy containing theCHKBgene. In the immortalized lymphocytes from patient 1, decreased expression ofCHKBwas revealed by quantitative PCR and western blot, and giant mitochondria were observed using electron microscopy.Conclusion: We provide a possibility to detect giant mitochondria in other cells when muscle was not available. Moreover, clinicians should be aware that homozygous variants can be masqueraded by uniparental disomy or large deletions in offspring of non‐consanguineous parents, and excessive homozygosity may be misdiagnosed.
- 6 January 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (6) , 533-555
Viral-mediated gene therapy in pediatric neurological disorders
Background Due to the broad application of next-generation sequencing, the molecular diagnosis of genetic disorders in pediatric neurology is no longer an unachievable goal. However, treatments for neurological genetic disorders in children remain primarily symptomatic. On the other hand, with the continuous evolution of therapeutic viral vectors, gene therapy is becoming a clinical reality. From this perspective, we wrote this review to illustrate the current state regarding viral-mediated gene therapy in childhood neurological disorders. Data sources We searched databases, including PubMed and Google Scholar, using the keywords "adenovirus vector," "lentivirus vector," and "AAV" for gene therapy, and "immunoreaction induced by gene therapy vectors," "administration routes of gene therapy vectors," and "gene therapy" with "NCL," “SMA,” “DMD,” “congenital myopathy,” “MPS” “leukodystrophy,” or “pediatric metabolic disorders”. We also screened the database of ClinicalTrials.gov using the keywords “gene therapy for children” and then filtered the results with the ones aimed at neurological disorders. The time range of the search procedure was from the inception of the databases to the present. Results We presented the characteristics of commonly used viral vectors for gene therapy for pediatric neurological disorders and summarized their merits and drawbacks, the administration routes of each vector, the research progress, and the clinical application status of viral-mediated gene therapy on pediatric neurological disorders. Conclusions Viral-mediated gene therapy is on the brink of broad clinical application. Viral-mediated gene therapy will dramatically change the treatment pattern of childhood neurological disorders, and many children with incurable diseases will meet the dawn of a cure. Nevertheless, the vectors must be optimized for better safety and efficacy.
- 6 January 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (6) , 533-555
Viral-mediated gene therapy in pediatric neurological disorders
Background Due to the broad application of next-generation sequencing, the molecular diagnosis of genetic disorders in pediatric neurology is no longer an unachievable goal. However, treatments for neurological genetic disorders in children remain primarily symptomatic. On the other hand, with the continuous evolution of therapeutic viral vectors, gene therapy is becoming a clinical reality. From this perspective, we wrote this review to illustrate the current state regarding viral-mediated gene therapy in childhood neurological disorders. Data sources We searched databases, including PubMed and Google Scholar, using the keywords "adenovirus vector," "lentivirus vector," and "AAV" for gene therapy, and "immunoreaction induced by gene therapy vectors," "administration routes of gene therapy vectors," and "gene therapy" with "NCL," “SMA,” “DMD,” “congenital myopathy,” “MPS” “leukodystrophy,” or “pediatric metabolic disorders”. We also screened the database of ClinicalTrials.gov using the keywords “gene therapy for children” and then filtered the results with the ones aimed at neurological disorders. The time range of the search procedure was from the inception of the databases to the present. Results We presented the characteristics of commonly used viral vectors for gene therapy for pediatric neurological disorders and summarized their merits and drawbacks, the administration routes of each vector, the research progress, and the clinical application status of viral-mediated gene therapy on pediatric neurological disorders. Conclusions Viral-mediated gene therapy is on the brink of broad clinical application. Viral-mediated gene therapy will dramatically change the treatment pattern of childhood neurological disorders, and many children with incurable diseases will meet the dawn of a cure. Nevertheless, the vectors must be optimized for better safety and efficacy.
- Open Access
- 20 April 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 877175
Restoration of Sarco/Endoplasmic Reticulum Ca2+-ATPase Activity Functions as a Pivotal Therapeutic Target of Anti-Glutamate-Induced Excitotoxicity to Attenuate Endoplasmic Reticulum Ca2+ Depletion
Glutamate-induced excitotoxicity is a pathological basis of many acute/chronic neurodegenerative diseases. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2b) is a membrane-embedded P-type ATPase pump that manages the translocation of calcium ions (Ca2+) from cytosol into the lumen of the endoplasmic reticulum (ER) calcium stores. It participates in a wide range of biological functions in the central nervous system (CNS). However, the role of SERCA2b in glutamate-induced excitotoxicity and its mechanism must be elucidated. Herein, we demonstrate that SERCA2b mutants exacerbate the excitotoxicity of hypo-glutamate stimulation on HT22 cells. In this study, SERCA2b mutants accelerated Ca2+ depletion through loss-of-function (reduced pumping capacity) or gain-of-function (acquired leakage), resulting in ER stress. In addition, the occurrence of ER Ca2+ depletion increased mitochondria-associated membrane formation, which led to mitochondrial Ca2+ overload and dysfunction. Moreover, the enhancement of SERCA2b pumping capacity or inhibition of Ca2+ leakage attenuated Ca2+ depletion and impeded excitotoxicity in response to hypo-glutamate stimulation. In conclusion, SERCA2b mutants exacerbate ER Ca2+-depletion-mediated excitotoxicity in glutamate-sensitive HT22 cells. The mechanism of disruption is mainly related to the heterogeneity of SERCA2b mutation sites. Stabilization of SRECA2b function is a critical therapeutic approach against glutamate-induced excitotoxicity. These data will expand understanding of organelle regulatory networks and facilitate the discovery and creation of drugs against excitatory/inhibitory imbalance in the CNS.
- 20 April 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 877175
Open AccessRestoration of Sarco/Endoplasmic Reticulum Ca2+-ATPase Activity Functions as a Pivotal Therapeutic Target of Anti-Glutamate-Induced Excitotoxicity to Attenuate Endoplasmic Reticulum Ca2+ Depletion
Glutamate-induced excitotoxicity is a pathological basis of many acute/chronic neurodegenerative diseases. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2b) is a membrane-embedded P-type ATPase pump that manages the translocation of calcium ions (Ca2+) from cytosol into the lumen of the endoplasmic reticulum (ER) calcium stores. It participates in a wide range of biological functions in the central nervous system (CNS). However, the role of SERCA2b in glutamate-induced excitotoxicity and its mechanism must be elucidated. Herein, we demonstrate that SERCA2b mutants exacerbate the excitotoxicity of hypo-glutamate stimulation on HT22 cells. In this study, SERCA2b mutants accelerated Ca2+ depletion through loss-of-function (reduced pumping capacity) or gain-of-function (acquired leakage), resulting in ER stress. In addition, the occurrence of ER Ca2+ depletion increased mitochondria-associated membrane formation, which led to mitochondrial Ca2+ overload and dysfunction. Moreover, the enhancement of SERCA2b pumping capacity or inhibition of Ca2+ leakage attenuated Ca2+ depletion and impeded excitotoxicity in response to hypo-glutamate stimulation. In conclusion, SERCA2b mutants exacerbate ER Ca2+-depletion-mediated excitotoxicity in glutamate-sensitive HT22 cells. The mechanism of disruption is mainly related to the heterogeneity of SERCA2b mutation sites. Stabilization of SRECA2b function is a critical therapeutic approach against glutamate-induced excitotoxicity. These data will expand understanding of organelle regulatory networks and facilitate the discovery and creation of drugs against excitatory/inhibitory imbalance in the CNS.